Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | LMNA | P02545 | 1/20 | 0.75 |
| ▸ | XDH | P47989 | 3/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | P4HB | P07237 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14360690 | 0.88 | KDM4E (0.58) | KDM4EALDH1A1HPGDLMNAXDH | |
| SCHEMBL1771123 | 0.86 | HPGD (1.00) | KDM4EALDH1A1HPGDLMNAPOLB | |
| SCHEMBL12596874 | 0.86 | KDM4E (0.77) | KDM4EALDH1A1HPGDLMNAXDH | |
| SCHEMBL25547757 | 0.86 | KDM4E (0.56) | KDM4EALDH1A1HPGDLMNAXDH | |
| SCHEMBL3555723 | 0.84 | HPGD (0.75) | KDM4EALDH1A1HPGDLMNAXDH | |
| SCHEMBL28941241 | 0.84 | KDM4E (0.75) | KDM4EALDH1A1HPGDLMNAGAA | |
| Hydrochloric Acid SCHEMBL3555727 | 0.84 | HPGD (0.97) | KDM4EALDH1A1HPGDLMNAPOLB | |
| SCHEMBL30503469 | 0.84 | KDM4E (0.75) | KDM4EALDH1A1HPGDLMNAGAA | |
| SCHEMBL12848655 | 0.82 | ALDH1A1 (0.71) | KDM4EALDH1A1HPGDLMNAGAA | |
| SCHEMBL12392288 | 0.82 | KDM4E (0.71) | KDM4EALDH1A1HPGDLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023118961-A1 | ANTIBODY DRUG CONJUGATES COMPRISING TOXINS WITH POLAR GROUPS AND USES THEREOF | INTOCELL, INC. (KR) | 2023-06-29 | — | — | WO | disclosed |
| WO-2021260438-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING ANTI-B7-H3 ANTIBODIES | INTOCELL, INC. (KR) | 2021-12-30 | — | — | WO | disclosed |
| CN-103601670-B | The similar thing of piperlongumine and its preparation method and application | 中国人民解放军第二军医大学 | 2016-06-15 | — | — | CN | disclosed |
| CN-103601670-A | Piplartine analogue, and preparation method and application thereof | UNIV PLA 2ND MILITARY MEDICAL | 2014-02-26 | — | — | CN | disclosed |
| WO-2012084971-A1 | INDOLE DERIVATIVES AS AGENTS AGAINST GRAM-NEGATIVE AND GRAM-POSITIVE BACTERIA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2012-06-28 | — | — | WO | disclosed |
| EP-1400510-B1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | KOWA CO (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-7135473-B2 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2006-11-14 | — | — | US | disclosed |
| CN-1281585-C | Cyclic diamine compounds having fused-ring groups | KOWA CO (JP) | 2006-10-25 | — | — | CN | disclosed |
| CN-1599717-A | Cyclic diamine compounds having fused-ring groups | KOWA CO (JP) | 2005-03-23 | — | — | CN | disclosed |
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2004-03-25 | — | — | US | disclosed |
| EP-1400510-A1 | CYCLIC DIAMINE COMPOUNDS HAVING FUSED-RING GROUPS | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6632810-B2 | Such as N,N'-bis((5,6,7-trimethoxynaphthalen-2-yl)methyl) piperazine, which has inhibitory effects on cell adhesion, for treatment of allergy, asthma, rheumatism, arteriosclerosis, and inflammation | KOWA CO., LTD. (JP) | 2003-10-14 | — | — | US | disclosed |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | KOWA CO., LTD. (JP) | 2003-03-27 | — | — | US | disclosed |
| EP-1011665-A4 | HETEROCYCLIC AGENTS | LILLY CO ELI (US) | 2001-09-12 | — | — | EP | disclosed |
| EP-1011665-A1 | HETEROCYCLIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998040068-A1 | HETEROCYCLIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058913-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | KDM4E 2052/4885ALDH1A1 468/4885HPGD 2236/4885 |
| US-20030060461-A1 | Cyclic diamine compound with condensed-ring groups | HRH4, HRH3, HRH1 | KDM4E 2052/4885ALDH1A1 468/4885HPGD 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.